Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921144 | 1.00 | — | — | |
| SCHEMBL8069136 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL9308087 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8076688 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8083458 | 1.00 | — | — | |
| SCHEMBL7989464 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL8078463 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL11644266 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| SCHEMBL11652315 | 1.00 | DNM1 (0.50) | DNM1CA12CA1CA2CA3 | |
| Hydrochloric Acid SCHEMBL3508306 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115209922-A | Conjugates and uses thereof | 南京桦冠生物技术有限公司 | 2022-10-18 | — | — | CN | disclosed |
| US-9732341-B2 | Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers | TRANSLATE BIO MA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732340-B2 | Multimeric oligonucleotides compounds having cleavable linkers | TRANSLATE BIO MA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170211065-A1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | RANA THERAPEUTICS, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-9580708-B2 | Multimeric oligonucleotides compounds | RANA THERAPEUTICS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150315587-A1 | MULTIMERIC OLIGONUCLEOTIDES COMPOUNDS HAVING CLEAVABLE LINKERS | RANA THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315588-A1 | METHODS OF DELIVERING MULTIPLE TARGETING OLIGONUCLEOTIDES TO A CELL USING CLEAVABLE LINKERS | RANA THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150299695-A1 | MULTIMERIC OLIGONUCLEOTIDES COMPOUNDS | RANA THERAPEUTICS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | DARA BIOSCIENCES, INC. | 2011-09-22 | — | — | US | disclosed |
| EP-2309859-A1 | ENZYME INHIBITORS AND THE USE THEREOF | Dara Biosciences, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010008473-A1 | ENZYME INHIBITORS AND THE USE THEREOF | DARA BIOSCIENCES, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | GAA, CYP17A1, HSD17B11 | DNM1 3975/4885CA12 1714/4885CA1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.